INAXAPLIN

  INAXAPLIN, 2446816-88-0 2446816-88-0 S2SJ2RVZ6Y UNII-S2SJ2RVZ6Y C21H18F3N3O3 3-[5,7-difluoro-2-(4-fluorophenyl)-1H-indol-3-yl]-N-[(3S,4R)-4-hydroxy-2-oxopyrrolidin-3-yl]propanamide Inaxaplin (VX-147) is a small-molecule apolipoprotein L1 inhibitor developed by Vertex Pharmaceuticals for APOL1-mediated kidney disease. In preliminary studies the drug has shown promise in treating people with kidney disease and multiple gain of function mutations on the APOL1 gene.[1][2]     FSGS is a disease of the podocyte (glomerular visceral epithelial cells) …

Golcadomide (CC-99282)

  Golcadomide (CC-99282) Molecular Weight 535.57 Formula C28H30FN5O5 CAS No. 2379572-34-4 (S)-2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione 2-[(3S)-2,6-dioxopiperidin-3-yl]-4-[[2-fluoro-4-[(3-morpholin-4-ylazetidin-1-yl)methyl]phenyl]methylamino]isoindole-1,3-dione 2-[(3S)-2,6-Dioxo-3-piperidinyl]-4-[[[2-fluoro-4-[[3-(4-morpholinyl)-1-azetidinyl]methyl]phenyl]methyl]amino]-1H-isoindole-1,3(2H)-dione (ACI) (S)-2-(2,6-Dioxopiperidin-3-yl)-4-[[2-fluoro-4-[(3-morpholinoazetidin-1-yl)methyl]benzyl]amino]isoindoline-1,3-dione CC 1007548 CC 99282 CC-99282 CC1007548 Golcadomide WHO 12305 Golcadomide HCl, 2639939-36-7 Chemical Name: CC-99282 Hydrochloride; 2-[(3S)-2,6-Dioxopiperidin-3-yl]-4-[[2-fluoro-4-[(3-morpholin-4-ylazetidin-1-yl)methyl]phenyl]methylamino]isoindole-1,3-dione hydrochloride Novel potent and orally active cereblon (CRBN) E3 ligase modulator Ref: https://www.sciencedirect.com/science/article/abs/pii/S0268960X22000686 Golcadomide is a modulator of the E3 ubiquitin ligase complex containing …

Igermetostat

  Igermetostat C32H46N4O4. 550.73 2409538-60-7 2KES6YSH8D INN 12655 BENZAMIDE, N-((1,2-DIHYDRO-4,6-DIMETHYL-2-OXO-3-PYRIDINYL)METHYL)-3-(ETHYL(TETRAHYDRO-2H-PYRAN-4-YL)AMINO)-2-METHYL-5-((TRANS-3-(1-PIPERIDINYL)CYCLOBUTYL)OXY)- IGERMETOSTAT IGERMETOSTAT [INN] N-((1,2-DIHYDRO-4,6-DIMETHYL-2-OXO-3-PYRIDINYL)METHYL)-3-(ETHYL(TETRAHYDRO-2H-PYRAN-4-YL)AMINO)-2-METHYL-5-((TRANS-3-(1-PIPERIDINYL)CYCLOBUTYL)OXY)BENZAMIDE N-((4,6-DIMETHYL-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL)-3-(ETHYL(OXAN-4-YL)AMINO)-2-METHYL-5-(((1R,3R)-3-(PIPERIDIN-1-YL)CYCLOBUTYL)OXY)BENZAMIDE PATENT https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020020374&_cid=P22-LR1SQG-34075-1 PATENT US20230382898 https://patentscope.wipo.int/search/en/detail.jsf?docId=US415363922&_cid=P22-LR1S46-25135-1 The compound has been disclosed in patent WO2020020374A1. It is an enhancer of Zeste homolog 2 (EZH2) inhibitor, and can be used for preventing or treating EZH2-mediated diseases, including brain cancer, thyroid cancer, cardiac sarcoma, lung cancer, …

Oditrasertib,

  Obeldesivir, 2647441-36-7 361.35 g/mol C16H19N5O5 [(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methyl 2-methylpropanoate Q55KCM7PXB; ATV006; UNII-Q55KCM7PXB   Obeldesivir (GS-5245, ATV006) is an isobutyric ester prodrug of GS-441524 made by Gilead Sciences that is currently in Phase III trials for the outpatient treatment of COVID-19 in high risk patients.[1][2] The purpose of the isobutyric ester modification on obeldesivir is to improve the oral bioavailability of the parent nucleoside, GS-441524. Obeldesivir is hydrolyzed to its parent nucleoside, GS-441524, which is in turn …

Oditrasertib

Oditrasertib Molecular Formula C14H15F2N3O2 Molecular Weight 295.2846 UNII-I1YQT8HC89 I1YQT8HC89 cas 2252271-93-3 4-(3,3-Difluoro-2,2-dimethylpropanoyl)-3,5-dihydro-2H-pyrido(3,4-F)(1,4)oxazepine-9-carbonitrile PYRIDO(3,4-F)-1,4-OXAZEPINE-9-CARBONITRILE, 4-(3,3-DIFLUORO-2,2-DIMETHYL-1-OXOPROPYL)-2,3,4,5-TETRAHYDRO- Oditrasertib is a serine/threonine kinase (STK) inhibitor. PATENT [WO2018213632A1] https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018213632 AS ON DEC2021 3,491,869 VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT join me on Linkedin Anthony Melvin Crasto Ph.D – India | LinkedIn join me on Researchgate RESEARCHGATE join me on Facebook Anthony …

ORZILOBEN

  ORZILOBEN, CAS 1555822-28-0  2-methyl-3-(pentyloxy)benzoic acid Molecular Weight 222.28 Formula C13H18O3 Orziloben is a medium chain fatty acid (MCFA) analogue[1]. Patent WO2020074964 https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020074964&_cid=P12-LQYZJX-26404-1 The rising global epidemic of obesity and its comorbidities, e.g., type 2 diabetes mellitus and hyperlipidemia, is placing an enormous burden both on public health (mortality and morbidity) and on the available …

Opevesostat

Opevesostat ODM208 2231294-96-3 Chemical Formula: C21H26N2O5S Molecular Weight: 418.508 2-[(1,3-dihydro-2H-isoindol-2-yl)methyl]-5-{[1-(methanesulfonyl)piperidin-4-yl]methoxy}-4H-pyran-4-one Opevesostat tosylate 2832831-08-8 Molecular Formula C21H26N2O5S.C7H8O3S Molecular Weight 590.71 4H-Pyran-4-one, 2-[(1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[[1-(methylsulfonyl)-4-piperidinyl]methoxy]-, 4-methylbenzenesulfonate (1:1) 2-((1,3-DIHYDRO-2H-ISOINDOL-2-YL)METHYL)-5-((1-(METHYLSULFONYL)-4-PIPERIDINYL)METHOXY)-4H-PYRAN-4-ONE, TOSYLATE useful in the treatment of a steroid receptor, in particular androgen receptor (AR), dependent conditions and diseases, and to pharmaceutical compositions containing such compounds. Prostate cancer is worldwide the most …

Sotuletinib HCl

  Sotuletinib HCl CAS: 2222138-31-8 (HCl) Chemical Formula: C20H23ClN4O3S Molecular Weight: 434.939 7W3V82OQ0P Synonym: Sotuletinib HCl; Sotuletinib hydrochloride, Sotuletinib monohydrochloride, BLZ945; BLZ 945; BLZ-945; IUPAC/Chemical Name: 4-((2-(((1R,2R)-2-hydroxycyclohexyl)amino)benzo[d]thiazol-6-yl)oxy)-N-methylpicolinamide hydrochloride 2-PYRIDINECARBOXAMIDE, 4-((2-(((1R,2R)-2-HYDROXYCYCLOHEXYL)AMINO)-6-BENZOTHIAZOLYL)OXY)-N-METHYL- Sotuletinib, also known as BLZ945, is a potent and selective CSF-1R kinase inhibitor. BLZ945 showed effects of CSF1R inhibition on other tumor-infiltrating immune cells. BLZ945 attenuates the …

TACACICLIB, AUR-102, AURIGENE

  Tacaciclib 2768774-66-7 AUR-102 Tacaciclib SCHEMBL24548621 GTPL12880 528.6 g/mol C30H36N6O3 INN 12755 UNI D3G4JKK1MA (2S)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-methyl-2-[3-[6-[[(E)-4-morpholin-4-ylbut-2-enoyl]amino]pyridin-3-yl]phenyl]butanamide (αS)-N-(5-Cyclopropyl-1H-pyrazol-3-yl)-α-(1-methylethyl)-3-[6-[[(2E)-4-(4-morpholinyl)-1-oxo-2-buten-1-yl]amino]-3-pyridinyl]benzeneacetamide Benzeneacetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-α-(1-methylethyl)-3-[6-[[(2E)-4-(4-morpholinyl)-1-oxo-2-buten-1-yl]amino]-3-pyridinyl]-, (αS)- Tacaciclib is a CDK inhibitor, antineoplastic effect. The present invention is directed to methods of preparation of compound of formula (I) that is useful for inhibiting Cyclin-dependent kinase 7 (CDK7) and for treating diseases or disorders mediated thereby. CDK7, which …

Capivasertib

Capivasertib C21H25ClN6O2 428.915 1143532-39-1 AZD 5363 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE FDA APPROVED 11/16/2023, To treat breast cancer that meets certain disease criteria, Truqap Capivasertib, sold under the brand name Truqap, is an anti-cancer medication used for the treatment of breast cancer.[1][2] The most common adverse reactions include diarrhea, cutaneous adverse reactions, increased random glucose, decreased lymphocytes, decreased hemoglobin, increased fasting glucose, nausea, fatigue, decreased …